Nymox

NYMX NASDAQ
1.590
+0.050
+3.25%
After Hours: 1.590 0 0.00% 16:35 05/24 EDT
Open
1.610
Prev Close
1.540
High
1.610
Low
1.570
Volume
73.43K
Avg Vol (3M)
83.92K
52 Week High
3.900
52 Week Low
1.250
% Turnover
0.11%
Market Cap
108.00M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Related

Webull offers Nymox NYMX stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Nymox Pharmaceutical Corp is a Canada-based biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company operates through the research and development of products for the aging population segment. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also owns rights for its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex, Inc. conducts research and development, and manufacturing of NicAlert and TobacAlert.
MORE >

Recently

Name
Price
%Change